Tuesday, April 23, 2013

EASL: Sofosbuvir - HCV Targeting Therapy Shows More Promise

Related @ Medscape - Rapid, Sustained Response With Sofosbuvir in Hepatitis C

HCV-Targeting Therapy Shows More Promise

Published: April 23, 2013
  • An investigational drug (sofosbuvir) that acts directly against the hepatitis C virus (HCV) works quickly and effectively.
  • Point out that in the NEUTRINO and FISSION studies, the most common adverse events were fatigue, headache, nausea, and insomnia.

No comments:

Post a Comment